Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02496143 · ClinicalTrials.gov registry record · Phase 1
A Safety and PK Study of EC-18 in Healthy Subjects
A Phase 1 study of Chemotherapy-induced Neutropenia, sponsored by Enzychem Lifesciences Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT02496143: Completed Phase 1 study of Chemotherapy-induced Neutropenia, sponsored by Enzychem Lifesciences Corporation.
NCT02496143 is a Phase 1 study of Chemotherapy-induced Neutropenia that has completed, run by Enzychem Lifesciences Corporation. The registered enrollment target is 33 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (45% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02496143, a Phase 1 study of Chemotherapy-induced Neutropenia, has completed, sponsored by Enzychem Lifesciences Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if EC-18 is safe and tolerable in healthy subjects.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG EC-18
Study Locations (1)
North Carolina
- Carolina Phase I Clinical Research - Raleigh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2015-07 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
What the finished NCT02496143 record still lists
NCT02496143 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (45% lower).
The record links to 1 condition, with Chemotherapy-induced Neutropenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02496143 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT02496143 about?
NCT02496143 is a clinical study titled "A Safety and PK Study of EC-18 in Healthy Subjects". The purpose of this study is to determine if EC-18 is safe and tolerable in healthy subjects.
What is the current status of trial NCT02496143?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2015-07. Estimated completion is 2015-12.
What conditions does trial NCT02496143 study?
This clinical trial studies the following conditions: Chemotherapy-induced Neutropenia.
What interventions are being tested in trial NCT02496143?
The interventions under investigation include: Placebo (DRUG), EC-18 (DRUG).
Who is sponsoring clinical trial NCT02496143?
This trial is sponsored by Enzychem Lifesciences Corporation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02496143 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chemotherapy-induced Neutropenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02496143's enrollment target sits among peer trials
33 1280th of 2000 higher than 705 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia